NCT04829344View on ClinicalTrials.gov

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

May 6, 2021

Study Completion Date

May 10, 2021

Conditions
Anesthesia, Local
Interventions
DRUG

AG-920

AG-920 Sterile Topical Ophthalmic Solution

DRUG

Placebo

Placebo Topical Ophthalmic Solution

Trial Locations (1)

78503

American Genomics Site 2, McAllen

Sponsors
All Listed Sponsors
lead

American Genomics, LLC

INDUSTRY

NCT04829344 - A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution | Biotech Hunter | Biotech Hunter